SNN, ALXN And ACT, 3 Health Care Stocks Pushing The Sector Lower

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading up today with the Dow Jones Industrial Average ( ^DJI) trading up 8 points (0.0%) at 17,140 as of Wednesday, Sept. 17, 2014, 12:55 PM ET. The NYSE advances/declines ratio sits at 1,738 issues advancing vs. 1,242 declining with 174 unchanged.

The Health Care sector currently sits up 0.6% versus the S&P 500, which is unchanged. On the negative front, top decliners within the sector include Baxter International ( BAX), down 2.8%, Gilead ( GILD), down 1.7%, DaVita HealthCare Partners ( DVA), down 1.3%, Medtronic ( MDT), down 0.9% and Covidien ( COV), down 0.9%. Top gainers within the sector include Auxilium Pharmaceuticals ( AUXL), up 44.2%, Endo International ( ENDP), up 6.7%, Alnylam Pharmaceuticals ( ALNY), up 4.8%, Abbott Laboratories ( ABT), up 1.3% and Sanofi ( SNY), up 1.2%.

TheStreet would like to highlight 3 stocks pushing the sector lower today:

3. Smith & Nephew ( SNN) is one of the companies pushing the Health Care sector lower today. As of noon trading, Smith & Nephew is down $1.19 (-1.4%) to $85.72 on heavy volume. Thus far, 113,399 shares of Smith & Nephew exchanged hands as compared to its average daily volume of 142,200 shares. The stock has ranged in price between $85.04-$86.15 after having opened the day at $85.60 as compared to the previous trading day's close of $86.91.

Smith & Nephew plc develops, manufactures, markets, and sells medical devices in the advanced surgical devices and advanced wound management sectors worldwide. Smith & Nephew has a market cap of $15.7 billion and is part of the health services industry. Shares are up 21.1% year-to-date as of the close of trading on Tuesday. Currently there are 4 analysts that rate Smith & Nephew a buy, no analysts rate it a sell, and 4 rate it a hold.

TheStreet Ratings rates Smith & Nephew as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, expanding profit margins, solid stock price performance and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Smith & Nephew Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

2. As of noon trading, Alexion Pharmaceuticals ( ALXN) is down $2.00 (-1.2%) to $161.41 on light volume. Thus far, 318,104 shares of Alexion Pharmaceuticals exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $161.18-$164.62 after having opened the day at $164.31 as compared to the previous trading day's close of $163.41.

Alexion Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes life-transforming therapeutic products. Alexion Pharmaceuticals has a market cap of $31.7 billion and is part of the drugs industry. Shares are up 23.0% year-to-date as of the close of trading on Tuesday. Currently there are 12 analysts that rate Alexion Pharmaceuticals a buy, no analysts rate it a sell, and 3 rate it a hold.

TheStreet Ratings rates Alexion Pharmaceuticals as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, expanding profit margins, good cash flow from operations and solid stock price performance. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Get the full Alexion Pharmaceuticals Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

1. As of noon trading, Actavis ( ACT) is down $3.12 (-1.3%) to $235.64 on average volume. Thus far, 1.4 million shares of Actavis exchanged hands as compared to its average daily volume of 2.3 million shares. The stock has ranged in price between $233.53-$238.78 after having opened the day at $238.78 as compared to the previous trading day's close of $238.76.

Actavis plc, an integrated specialty pharmaceutical company, is engaged in the development, manufacture, marketing, sale, and distribution of pharmaceutical products in the Americas, Europe, the Middle East, Africa, Australia, and the Asia Pacific. Actavis has a market cap of $62.1 billion and is part of the drugs industry. Shares are up 42.1% year-to-date as of the close of trading on Tuesday. Currently there are 16 analysts that rate Actavis a buy, no analysts rate it a sell, and none rate it a hold.

TheStreet Ratings rates Actavis as a hold. The company's strengths can be seen in multiple areas, such as its robust revenue growth, compelling growth in net income and good cash flow from operations. However, as a counter to these strengths, we find that the company has favored debt over equity in the management of its balance sheet. Get the full Actavis Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.

If you are interested in one of these 3 stocks, ETFs may be of interest. Investors who are bullish on the health care sector could consider Health Care Select Sector SPDR ( XLV) while those bearish on the health care sector could consider ProShares Ultra Short Health Care ( RXD).

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers